<DOC>
	<DOCNO>NCT01223326</DOCNO>
	<brief_summary>Study hypothesis : N-acetylcysteine ( NAC ) reduce ischemia/reperfusion injury liver resection perform ischemic preconditioning intermittent portal triad clamping .</brief_summary>
	<brief_title>N-acetylcysteine Reduce Ischemia/Reperfusion Injury Liver Resection</brief_title>
	<detailed_description>One important factor pathophysiology liver dysfunction hepatic surgery cellular damage derive interruption blood flood reperfusion organ . N-acetylcysteine ( NAC ) prove beneficial several condition involve oxidative damage . This study investigate effect NAC reduce ischemia/reperfusion injury liver resection perform ischemic preconditioning intermittent portal triad clamping . Methods : 46 ASA II-III patient schedule undergo liver resection randomise receive NAC ( initial dose : 150 mg/Kg ; infusion 50 mg/kg , 30 minute ischemia 60 minute later reperfusion ) placebo phase IV clinical trial . Blood , hepatic urinary marker obtain basal status 1 , 3 24 h post final reperfusion .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Hepatectomy ASA 4 Cirrhosis Creatinine &gt; 1.2 mg/dL Associate surgery ( pancreatic splenectomy ) Intraoperative bleed &gt; 2 L. Active infection inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Acetylcysteine</keyword>
</DOC>